10.5061/DRYAD.J6Q573NC3
Blazhenets, Ganna
0000-0003-2419-7373
University of Freiburg
Frings, Lars
University of Freiburg
Ma, Yilong
Feinstein Institute for Medical Research
Sörensen, Arnd
University of Freiburg
Eidelberg, David
Feinstein Institute for Medical Research
Wiltfang, Jens
University of Göttingen
Meyer, Philipp T.
University of Freiburg
Validation of the AD dementia conversion-related pattern as an ATN
biomarker of neurodegeneration: Supplemental material
Dryad
dataset
2020
2021-11-10T00:00:00Z
2021-03-09T00:00:00Z
en
https://doi.org/10.1212/WNL.0000000000011521
983292 bytes
3
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Objective: To determine whether the Alzheimer’s disease dementia
conversion-related pattern (ADCRP) on [18F]FDG PET can serve as a valid
predictor for the development of Alzheimer’s disease dementia, the
individual expression of the ADCRP (subject score) and its prognostic
value were examined in subjects with mild cognitive impairment and
biologically defined Alzheimer’s disease. Methods: 269 subjects with
available [18F]FDG PET, [18F]AV-45 PET, phosphorylated and total tau in
CSF, and neurofilament light chain in plasma were included. Following the
AT(N) classification scheme, where Alzheimer’s disease is defined
biologically by in vivo biomarkers of Aβ deposition (“A”) and pathological
tau (“T”), subjects were categorized to the A-T-, A+T-, A+T+ (Alzheimer’s
disease), and A-T+ groups. Results: The mean subject score of the ADCRP
was significantly higher in the A+T+ group compared to each of the other
group (all p < 0.05) but was similar among the latter (all p
> 0.1). Within the A+T+ group, the subject score of ADCRP was a
significant predictor of conversion to dementia (HR = 2.02 per z-score
increase, p < 0.001), with higher predictive value than of
alternative biomarkers of neurodegeneration (total tau and neurofilament
light chain). Stratification of A+T+ subjects by the subject score of
ADCRP yielded well-separated groups of high, medium, and low conversion
risks. Conclusions: The ADCRP is a valuable biomarker of neurodegeneration
in subjects with mild cognitive impairment and biologically defined
Alzheimer’s disease. It shows great potential for stratifying the risk and
estimating the time to conversion to dementia in subjects with mild
cognitive impairment and underlying Alzheimer’s disease (A+T+).
Classification of Evidence: This study provides Class I evidence that
[18F]FDG PET predicts the development of AD dementia in individuals with
MCI and underlying AD as defined by the AT(N) framework.